Sun Pharmaceutical Industries Limited — Q1FY27 earnings call summary

Filed 06 August 2026 · Official transcript

Q1 FY27 consolidated sales grew 10.1% y-y to INR151,836 million; EBITDA margin 28.9%
R&D spend at 5.4% of sales; 30% on innovative medicines; Organon acquisition on track for Q4 FY27
Management expects high single-digit revenue growth for FY27; tax rate around 27.8%
Multiple analyst queries on specialty product ramp-up and US generics outlook; management expects sustained growth but no product-wise guidance
India formulations sales grew 16%, market share increased to 8.5%; volume growth 5.4%
Innovative medicines sales up 12.8% to USD351 million; driven by ILUMYA, ODOMZO, CEQUA
US sales declined 9.7% due to generic erosion; innovative portfolio growing with Leqselvi and Unloxcyt
Emerging markets sales up 4.2%; Rest of World flat at USD218 million